UBC Acquires REMS Company
Examoto is dedicated to the design, deployment, and operation of Risk Evaluation and Mitigation Strategy (REMS) services in the pharmaceutical market
UBC (Blue Bell, PA), a company providing integrated clinical, safety, and commercialization services for the biopharma industry, has announced that it has acquired Examoto, LLC, a Risk Evaluation and Mitigation Strategy (REMS) firm.
Examoto founder Jason Leedy commented, “Examoto’s technology and design innovations, in concert with UBC’s Project Management Office and related REMS services, creates a REMS powerhouse. We will collectively have the most comprehensive, proven capabilities for risk mitigation solutions for the pharma industry.”
Natalie O’Donnell, corporate vice president, UBC Safety and Risk Management, added, “Our acquisition of Examoto helps cement UBC’s status as a preeminent leader in this category, with a full-service REMS solution that leverages enhanced technologies and product innovations to help mitigate safety risk while optimizing the commercialization and delivery of products to market.”
FDA Approves Actemra Biosimilar
January 31st 2025Celltrion’s Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19—in the same dosages and formulations as its tocilizumab reference product.
